Key Points
-
The success of the tyrosine-kinase inhibitor STI571 (Gleevec/Glivec) in the treatment of chronic myelogenous leukaemia has spurred considerable efforts to develop other kinase inhibitors for the treatment of a wide range of cancers.
-
However, the molecularly targeted nature of these drugs poses several novel challenges in their clinical development as compared with the development of traditional cytotoxic drugs.
-
Issues considered in this review include:
-
Which kinase to target with what type of drug?
-
Which disease to target, and when?
-
How to build combinations with standard agents
-
Strategies to address the development challenges raised by these issues are put forward.
Abstract
Identification of the key roles of protein kinases in cancer has led to extensive efforts to develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 such agents are now in clinical trials. Here, we consider the crucial issues in the development of kinase inhibitors for cancer, and discuss strategies to address the challenges raised by these issues in the light of preclinical and clinical experiences so far.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Druker, B. J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21, 8541–8546 (2002).
Joensuu, H. et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3, 655–664 (2002).
Rubin, B. P. et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20, 3586–3591 (2002).
Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355–365 (2001).
Scappaticci, F. A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20, 3906–3927 (2002).
Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727–739 (2002).
Madhusudan, S. & Harris, A. L. Drug inhibition of angiogenesis. Curr. Opin. Pharmacol. 2, 403–414 (2002).
Yamada, K. M. & Araki, M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114, 2375–2382 (2001).
Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2, 289–300 (2002).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002). A comprehensive evaluation of cell lines and tumour histologies for a specific activating mutation that has led to the identification of a subset of tumours that might be evaluated with Raf-targeting agents.
van de Vijver, M. Emerging technologies for HER2 testing. Oncology 63 (Suppl. 1), 33–38 (2002).
Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001). Seminal paper demonstrating that the activity of a small-molecule tyrosine kinase inhibitor in a molecularly defined disease might be reduced in the presence of additional molecular abnormalities.
Davis, R. E. & Staudt, L. M. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr. Opin. Hematol. 9, 333–338 (2002).
Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8, 68–74 (2002).
van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790–13795 (2001).
Singh, D. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203–209 (2002). References 14–18 demonstrate that there are subsets of tumours within histologies with different clinical outcomes that can be defined by gene expression.
Seimiya, H., Mashima, T., Toho, M. & Tsuruo, T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1? converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 272, 4631–4636 (1997).
Bulavin, D. V., Amundson, S. A. & Fornace, A. J. p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr. Opin. Genet. Dev. 12, 92–97 (2002).
Grant, S. & Jarvis, W. D. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin. Cancer Res. 2, 1915–1920 (1996).
Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002).
Levitzki, A. The selectivity of small molecules towards protein tyrosine kinases. Ernst Schering Res. Found. Workshop 34, 71–80 (2001).
Levitzki, A. & Bohmer, F. D. Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases. Anticancer Drug Des. 13, 731–734 (1998).
Levitzki, A., Gazit, A., Osherov, N., Posner, I. & Gilon, C. Inhibition of protein-tyrosine kinases by tyrphostins. Methods Enzymol. 201, 347–361 (1991).
Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55–S61 (2002).
Kerkhoff, E. & Rapp, U. R. The Ras-Raf relationship: an unfinished puzzle. Adv. Enzyme Regul. 41, 261–267 (2001).
Fan, Z., Baselga, J., Masui, H. & Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53, 4637–4642 (1993).
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I. & Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885–4892. (2000).
Monks, A. et al. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest. New Drugs 18, 95–107 (2000).
Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P. & Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res. 3, 1467–1472 (1997).
Wilkinson, E. Surprise phase III failure for ZD1839. Lancet Oncol. 3, 583 (2002).
O'Connor, D. S., Wall, N. R., Porter, A. C. & Altieri, D. C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2, 43–54 (2002).
Wall, N. R., O'Connor, D. S., Plescia, J., Pommier, Y. & Altieri, D. C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 63, 230–235 (2003).
Kuenen, B. C. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657–1667 (2002).
Manley, P. W., Martiny-Baron, G., Schlaeppi, J. M. & Wood, J. M. Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs 11, 1715–1736 (2002).
Nahta, R., Iglehart, J. D., Kempkes, B. & Schmidt, E. V. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res. 62, 2267–2271 (2002).
Dai, Y. et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 61, 5106–5115 (2001).
Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052–1056 (2001). Seminal paper demonstrating the remarkable activity of small-molecule tyrosine kinase inhibitor in a malignancy defined by a specific activating mutation and for which previously there was no effective treatment.
Webb, C. P. et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60, 342–349 (2000).
Ntziachristos, V., Tung, C. H., Bremer, C. & Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo. Nat. Med. 8, 757–760 (2002).
Gallardo, G. et al. Regulation by ceramide of epidermal growth factor signal transduction and mitogenesis in cell lines overexpressing the growth factor receptor. Cell Mol. Biol. (Noisy-le-grand) 46, 1305–1312 (2000).
Eccles, S. A. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. Recent Results Cancer Res. 157, 41–54 (2000).
Sieg, D. J. et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2, 249–256 (2000).
Ciardiello, F. & Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958–2970 (2001).
Ciardiello, F. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053–2063 (2000).
Milas, L. et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6, 701–708 (2000).
Huang, S. M. & Harari, P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6, 2166–2174 (2000).
Pollack, V. A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291, 739–748 (1999).
Yang, X. -D., Wang, P., Fredlin, C. & Davis, C. G. ABX-EGF, a fully human anti-EGF receptor monoclonal antibody: inhibition of prostate cancer in vitro and in vivo. Proc. Am. Soc. Clin. Oncol. 21, 2454 (2002).
Lynch, D. H. & Yang, X. D. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol. 29, 47–50 (2002).
Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P. & Davis, C. G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38, 17–23 (2001).
Hambek, M. et al. Tumor necrosis factor α sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res. 61, 1045–1049 (2001).
Bishop, P. C. et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21, 119–127 (2002). Interesting attempt to correlate sensitivity to different EGFR inhibitors of the NCI 60 cell line screen and molecular profile.
Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20, S1–S13 (2002).
Baselga, J. et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904–914 (2000).
Figlin, R. A. et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc. Am. Soc. Clin. Oncol. 21, 35 (2002).
Kahn, M. E., Senderowicz, A., Sausville, E. A. & Barrett, K. E. Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clin. Cancer Res. 7, 343–349 (2001).
Swaisland, H., Smith, R. P., Farebrother, J. & Laight, A. The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral doses of ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in healthy male volunteers. Proc. Am. Soc. Clin. Oncol. 21, 328 (2002).
Baselga, J. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20, 4292–4302 (2002).
Herbst, R. S. et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20, 3815–3825 (2002).
Hidalgo, M. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267–3279 (2001).
Albanell, J. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20, 110–124 (2002). One of the few papers to incorporate a number of pharmacodynamic assays into a Phase I trial of a tyrosine kinase inhibitor
Saltz, L. et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 21, 504 (2002).
Perez-Soler, R. et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 1235 (2001).
Kris, M. G. et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21, 1166 (2002).
Fukuoka, M. et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 21, 1188 (2002).
Senzer, N. et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 20, 6 (2001).
Cohen, E. E. et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol. 21, 899 (2002).
Finkler, N. et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 20, 831 (2001).
Saltz, L. et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 20, 7 (2001).
Baselga, J. et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. 21, 900 (2002).
Burtness, B. A., Li, Y., Flood, W., Mattar, B. I. & Forastiere, A. A. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc. Am. Soc. Clin. Oncol. 21, 901 (2002).
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127–137 (2001).
Normanno, N. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65–72 (2002).
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. & Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 93, 1852–1857 (2001).
Chakravarti, A., Loeffler, J. S. & Dyson, N. J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62, 200–207 (2002).
Grunicke, H. H. & Maly, K. Role of GTPases and GTPase regulatory proteins in oncogenesis. Crit. Rev. Oncog. 4, 389–402 (1993).
Magee, T. & Marshall, C. New insights into the interaction of Ras with the plasma membrane. Cell 98, 9–12 (1999).
Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S. & Wetzker, R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 275, 394–397 (1997).
Kerkhoff, E. & Rapp, U. R. Cell cycle targets of Ras/Raf signalling. Oncogene 17, 1457–1462 (1998).
Pruitt, K. & Der, C. J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171, 1–10 (2001).
Pollock, P. M. & Meltzer, P. S. Lucky draw in the gene raffle. Nature 417, 906–907 (2002).
Sekido, Y., Fong, K. M. & Minna, J. D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta 1378, F21–59 (1998).
Stanton, V. P. Jr. & Cooper, G. M. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol. Cell Biol. 7, 1171–1179 (1987).
Kolch, W. et al. Protein kinase C α activates RAF-1 by direct phosphorylation. Nature 364, 249–252 (1993).
Cornwell, M. M. & Smith, D. E. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene C-raf kinase. J. Biol. Chem. 268, 15347–15350 (1993).
Monia, B. P. First- and second-generation antisense oligonucleotide inhibitors targeted against human C-raf kinase. Ciba Found. Symp. 209, 107–119 (1997).
McPhillips, F. et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br. J. Cancer 85, 1753–1758 (2001).
Lau, Q. C., Brusselbach, S. & Muller, R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 16, 1899–1902 (1998).
Langdon, S. et al. Antisense oligonucleotide (ISIS 5132) targeting of C-raf kinase in ovarian cancer models. Proc. Am. Soc. Clin. Oncol. 20, 833 (2001).
Geiger, T., Muller, M., Monia, B. P. & Fabbro, D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin. Cancer Res. 3, 1179–1185 (1997).
Stevenson, J. P. et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2227–2236 (1999).
Cunningham, C. C. et al. A phase I trial of C-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 6, 1626–1631 (2000).
Rubin, E. et al. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 on a 14- or 28-day dosing schedule. Proc. Am. Soc. Clin. Oncol. 21, 689 (2000).
O'Dwyer, P. J. et al. c-Raf-1 depletion and tumor responses in patients treated with the c- raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res. 5, 3977–3982 (1999).
Coudert, B. et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) early clinical studies group report. Eur. J. Cancer 37, 2194–2198 (2001).
Tolcher, A. W. et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 8, 2530–2535 (2002).
Cripps, M. C. et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin. Cancer Res. 8, 2188–2192 (2002).
Wilhelm, S. & Chien, D. -S. BAY 43-9006. Curr. Pharm. Des. 8, 2255–2257 (2002).
Vincent, P. et al. Chemotherapy with the raf kinase inhibitor BAY 43-9006 in combination with irinotecan, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenograft models. Proc. Am. Soc. Clin. Oncol. 21, 1900 (2002).
Strumberg, D. et al. Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 121 (2002).
Moore, M. et al. Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 1816 (2002).
Hilger, R. A. et al. Inhibition of ERK phosphorylation and clinical outcome in patients treated with the Raf kinase inhibitor BAY 43-9006. Proc. Am. Soc. Clin. Oncol. 21, 1916 (2002).
Catling, A. D., Schaeffer, H. J., Reuter, C. W., Reddy, G. R. & Weber, M. J. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol. Cell Biol. 15, 5214–5225 (1995).
Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594–6599 (2000).
Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5, 810–816 (1999).
LoRusso, P. M. et al. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 21, 321 (2002).
Stein, R. C. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr. Relat. Cancer 8, 237–248 (2001).
Stein, R. C. & Waterfield, M. D. PI3-kinase inhibition: a target for drug development? Mol. Med. Today 6, 347–357 (2000).
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002).
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
Sabers, C. J. et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 270, 815–822 (1995).
Schmelzle, T. & Hall, M. N. TOR, a central controller of cell growth. Cell 103, 253–262 (2000).
Rohde, J., Heitman, J. & Cardenas, M. E. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem. 276, 9583–9586 (2001).
Proud, C. G. & Denton, R. M. Molecular mechanisms for the control of translation by insulin. Biochem. J. 328, 329–341 (1997).
Douros, J. & Suffness, M. New antitumor substances of natural origin. Cancer Treat. Rev. 8, 63–87 (1981).
Eng, C. P., Sehgal, S. N. & Vezina, C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. (Tokyo) 37, 1231–1237 (1984).
Muthukkumar, S., Ramesh, T. M. & Bondada, S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60, 264–270 (1995).
Seufferlein, T. & Rozengurt, E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 56, 3895–3897 (1996).
Hosoi, H. et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol. 54, 815–824 (1998).
Hosoi, H. et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59, 886–894 (1999).
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G. & Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 59, 3581–3587 (1999).
Majewski, M. et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 97, 4285–4290 (2000).
Dudkin, L. et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7, 1758–1764 (2001).
Shi, Y. et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 55, 1982–1988 (1995).
Gibbons, J. J. et al. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc. Am. Assoc. Cancer Res. 40, 2000 (1999).
Geoerger, B. et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61, 1527–1532 (2001).
Hidalgo, M. et al. Phase I and pharmacological study of CCI-779, a cell cycle inhibitor. Clin. Cancer Res. (suppl) 6, 413 (2000).
Hidalgo, M. et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. Proc. Am. Soc. Clin. Oncol. 19, 726 (2000).
Raymond, E. et al. CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: A phase I study utilizing a weekly intravenous schedule. Clin. Cancer Res. (suppl) 6, 414 (2000).
Raymond, E. et al. CCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule. Proc. Am. Soc. Clin. Oncol. 19, 728 (2000).
Oz, H. S., Hughes, W. T., Varilek, G., McAlister, V. C. & MacDonald, A. S. Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti-pneumonitis effects of mycophenolate mofetil. Transplantation 72, 1464–1465 (2001).
Lennon, A., Finan, K., FitzGerald, M. X. & McCormick, P. A. Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 72, 1166–1167 (2001).
Chan, S. et al. First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol. 21, 175 (2002).
Atkins, M. B. et al. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21, 36 (2002).
Gallant, H. L. & Yatscoff, R. W. P70 S6 kinase assay: a pharmacodynamic monitoring strategy for rapamycin; assay development. Transplant. Proc. 28, 3058–3061 (1996).
Ferron, G. M., Pyszczynski, N. A. & Jusko, W. J. Gender-related assessment of cyclosporine/prednisolone/ sirolimus interactions in three human lymphocyte proliferation assays. Transplantation 65, 1203–1209 (1998).
Ferron, G. M. & Jusko, W. J. Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J. Pharmacol. Exp. Ther. 286, 191–200 (1998).
Marx, S. O. & Marks, A. R. Cell cycle progression and proliferation despite 4BP-1 dephosphorylation. Mol. Cell Biol. 19, 6041–6047 (1999).
Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314–10319 (2001).
Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl Acad. Sci. USA 98, 10320–10325 (2001).
Yu, K. et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8, 249–258 (2001).
Huang, S. et al. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res. 61, 3373–3381 (2001).
Wang, S., Wang, Z. & Grant, S. Bryostatin 1 and UCN-01 potentiate 1-β-d-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Mol. Pharmacol. 63, 232–242 (2003).
Cartee, L. et al. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol. Cancer Ther. 2, 83–93 (2003).
Rosato, R. R. et al. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther. 1, 253–266 (2002).
McKinstry, R. et al. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol. Ther. 1, 243–253 (2002).
Betensky, R. A., Louis, D. N. & Cairncross, J. G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20, 2495–2499 (2002). One of the first papers to highlight the effects of molecular heterogeneity within tumours of patients in a clinical trial can have on sample size and power if molecular phenotype determines the magnitude of response to treatment.
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001). Seminal paper demonstrating the benefit of an antibody directed against a receptor tyrosine kinase in a selected patient population.
Author information
Authors and Affiliations
Glossary
- METASTASIS
-
The dissemination of cancer cells via the bloodstream or lymphatic system to other parts of the body, where they produce further tissue damage.
- LYMPHOID
-
A term that describes the type of tissue found in the lymph nodes, tonsils, spleen, and thymus. It is responsible for producing lymphocytes and therefore contributes to the body's defence against infection.
- MYELOID
-
A term that describes tissue within red bone marrow that produces the blood cells.
- KARYOTYPE
-
A complete description of the chromosomes present in a cell. It is characterized by numerical and structural abnormalities in most cancers.
- FAMILIAL ADENOMATOUS POLYPOSIS
-
A genetic disorder characterized by the development of multiple intestinal polyps that are precursor lesions for colon carcinoma.
- THROMBOTIC
-
A term that describes the obstruction of a blood vessel by a mass of blood cells and fibrin (thrombus), which can result from excessive blood clotting.
- POSITRON EMISSION TOMOGRAPHY
-
An imaging technique that is used to detect decaying nuclides, such as 15O, 13N, 11C, 18F, 124I and 94mTc.
- TUMOUR XENOGRAFT
-
Generally refers to the growth of human tumour cells as tumours in immuno-compromised mice.
- IC50
-
The half-maximal inhibitory concentration.
- TRANSFORMING
-
A term that describes the processes through which normal cells acquire malignant character.
- PARTIAL THROMBOPLASTIN TIME
-
A test to assess the function of specific proteins required to form blood clots.
- ANASARCA
-
Generalized oedema.
- ERYTHEMA
-
Abnormal redness of skin.
- SKIN DESQUAMATION
-
Sloughing of skin layer.
- PEARSON CORRELATION COEFFICIENT
-
Pearson's correlation coefficient (r) expresses the degree of linear relationship. Pearson's r values can range between −1.00 to +1.00. A correlation coefficient of +1.00 signifies a perfect positive relationship, whereas −1.00 denotes a perfect negative relationship. The smallest correlation is zero.
- THROMBOCYTOPENIA
-
A reduction in the number of platelets.
- NEUTROPENIA
-
A reduction in the number of neutrophils.
- MUCOSITIS
-
Inflammation of the mucosa.
- ASTHENIA
-
Generalized weakness and debility.
- DYSPNOEA
-
Shortness of breath and discomfort of breathing.
- URTICARIA
-
Red itchy skin lesions.
- PRURITIS
-
Itchiness.
- FOLLICULITIS
-
Inflammation around hair follicles.
- LEUKOPENIA
-
Low white blood cell (leukocyte) count.
- STOMATITIS
-
Inflammation of the lining of the mouth.
- MYELOSUPPRESSION
-
Depressed production of blood cells deriving from the myeloid lineage, including platelets, some leukocytes and erythrocytes. Because many anticancer drugs suppress the growth or proliferation of rapidly dividing cells, myelosuppression is a common side effect.
- PNEUMONITIS
-
Inflammation of the lung tissues.
- PARACRINE
-
Describing an agent secreted from a cell that acts on other cells in the local environment.
- AUTOCRINE
-
Describing an agent secreted from a cell that acts on the cell in which it is produced.
Rights and permissions
About this article
Cite this article
Dancey, J., Sausville, E. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2, 296–313 (2003). https://doi.org/10.1038/nrd1066
Issue Date:
DOI: https://doi.org/10.1038/nrd1066
This article is cited by
-
Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core–shell protein nanoparticle
Drug Delivery and Translational Research (2022)
-
Identification of kinase inhibitors that rule out the CYP27B1-mediated activation of vitamin D: an integrated machine learning and structure-based drug designing approach
Molecular Diversity (2021)
-
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Journal for ImmunoTherapy of Cancer (2019)
-
Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway
European Journal of Medical Research (2019)
-
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
Cancers of the Head & Neck (2018)